Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
REPAY Stock Rises After Visa Platform Connect Collaboration 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Google to Move All Pixel Production Out of China by 2027 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Add as a preferred source on Google
The US International Trade Commission (ITC) upheld its preliminary ruling saying that South Korean drugmaker Daewoong Pharmaceutical Co. copied the manufacturing process of a botulinum toxin strain by local rival Medytox Inc. in Medytox Medytox
Consequently, the US trade panel ordered a 21-month ban on imports of Daewoong Pharmaceutical's botulinum products into the US.
ITC's ruling, however, reduces the initial 10-year ban prescribed by the preliminary panel that ruled that Daewoong's misappropriated trade secrets belonging to Medytox.
Medytox Inc. claimed that Daewoong's Jeuveau was developed using a trade secret stolen from it that turns the deadly botulinum toxin into a wrinkle treatment.
Daewoong denied any theft allegations or that any trade secret was involved and argued the US agency is not the proper forum to decide on the dispute.
